Sage Journals: Discover world-class research

Abstract

Background:

Elevated level of interleukin-8 (IL-8) promotes hepatocellular carcinoma (HCC) development and contributes to poor prognosis. Previously, we have proved that Dicer inhibits HCC progression. In this study, we evaluated the potential interaction between IL-8 and Dicer as well as their influence on HCC.

Methods:

Hepatocellular carcinoma cells of SMMC-7721 were divided into 2 groups for subsequent analysis: pCMV-Dicer group for Dicer-overexpressing lentivirus transfected cells (pCMV-Dicer cells) and pCMV-NC group for empty lentivirus transfected cells (pCMV-NC cells). Cell Counting kit-8 (CCK8), wound healing, and transwell were used to evaluate the inhibitory effect of Dicer overexpression on proliferation, migration, and invasion of HCC cells. The level of IL-8 was measured by flow cytometry bead-based immunoassays. Male nude BALB/c mice injected with pCMV-Dicer or pCMV-NC cell suspensions was used for transplant of HCC tumor.

Results:

We found that the secretion of IL-8 was reduced in the medium of pCMV-Dicer cells (P = .027). Recombinant human IL-8 (rhIL-8) reversed the inhibitory effect of Dicer on proliferation (P < .01), migration (P = .003), and invasion (P = .001), whereas IL-8 inhibitor of reparixin enhanced inhibitory effect of Dicer on proliferation (P < .05), migration (P = .008), and invasion (P = .000). Lenvatinib downregulated the IL-8 level of HCC cells (P = .000) as well as promote Dicer-induced inhibition for HCC cells referring to proliferation (P < .05), migration (P = .000), and invasion (P = .000). Animal experiments also demonstrated that Dicer cooperated with lenvatinib to inhibit the growth of HCC tumors (P < .05).

Conclusions:

Dicer cooperated with lenvatinib to inhibit HCC growth via downregulating IL-8, and Dicer displayed its potential capability to enhance the anti-tumor effect of lenvatinib.

Keywords

Dicer interleukin-8 reparixin lenvatinib hepatocellular carcinoma

Introduction

Primary liver cancer (PLC) is the seventh most common cancer and the second leading cause of cancer mortality worldwide, and approximately 75% of PLC is hepatocellular carcinoma (HCC).¹ In early stage of HCC, liver resection, liver transplant, and ablative techniques are efficient treatment methods.² However, about 40% of HCC patients are diagnosed at the advanced stage when surgery may not be effective, and the options for these patients include the administration of tyrosine kinase inhibitor (TKI), immune checkpoint inhibitors (ICIs), and anti-angiogenic drugs.^3,4 The TKI activity of lenvatinib showed noninferiority to sorafenib as the first-line treatment for HCC.^5,6 It can reduce the infiltration of regulatory T-cells (Tregs) and inhibit the transforming growth factor β (TGF-β) signaling pathway thereby improving tumor microenvironment.⁷ The overall response rate of lenvatinib is only 24% with the mechanisms of drug resistance unknown.⁸

MicroRNAs (miRNAs) are small noncoding RNAs that have 18 to 25 nucleotides, binding to the 3′-untranslated target region to regulate cell proliferation, differentiation, and apoptosis, and influence tumor progression and metastasis.^9,10 Dicer is a cytoplasmic RNaseIII enzyme involved in cell proliferation and apoptosis by cleaving premicroRNAs into mature microRNAs and short interfering RNAs in the cytoplasm.¹¹ Low expression of Dicer is related to poor prognosis in cancer patients including breast cancer,¹² gastric cancer,¹³ clear cell renal cell carcinoma,¹⁴ and colorectal cancer.¹⁵ We confirmed previously that Dicer-suppressed HCC by inhibiting the proliferation, invasion, and migration of HCC cells.¹⁶ We also found that Dicer enhanced the bevacizumab-related inhibition of HCC by blocking vascular endothelial growth factor (VEGF) pathway; however, the underlying mechanism has not been clarified.¹⁷

Interleukin-8 (IL-8), also known as CXCL8, is an important chemokine of the CXC family responsible for the recruitment and activation of neutrophils at inflammation sites. Not only malignant tumor cells but also myeloid cells and fibroblasts infiltrating tumors can produce IL-8.^18,19 C-X-C chemokine receptor 1 (CXCR1) and C-X-C chemokine receptor 2 (CXCR2) are the 2 specific receptors on the cell surface. IL-8 activates downstream signaling pathways by combining with CXCR1/2, participating in tumor cell proliferation, invasion, epithelial-mesenchymal transition (EMT), and angiogenesis.^20,21 Interleukin-8-CXCR1/2 remodels the tumor microenvironment by recruiting neutrophils and myeloid-derived suppressor cells (MDSCs).²² Elevated IL-8 is associated with poor prognosis in a variety of tumors such as head and neck squamous cell carcinoma,²³ ovarian cancer,²⁴ esophageal squamous cell carcinoma,²⁵ and gastric cancer.²⁶ In HCC, the up-regulation of IL-8 expression is also related to the enhancement of tumor cell malignant behaviors, leading to poor prognosis.²⁷ It could enhance the invasiveness of liver cancer cells by activating PI3K/Akt pathway.²⁸ Interleukin-8-CXCR1 axis enhances endothelium permeability to promote tumor cells vascular metastasis by increasing Tregs in liver cancer microenvironment.²⁹ In this study, we evaluated the interaction of Dicer with IL-8 as well as their influence on HCC progression.

Materials and Methods

Cell culture and transfection

Human HCC cell line SMMC-7721 was obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbecco’s Modified Eagle Medium (DMEM; Gibco Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS; Gibco Life Technologies, Grand Island, NY). The cells were incubated in a humidified incubator containing 5% CO₂ at 37°C. Recombinant human IL-8 (rhIL-8, 110719) was purchased from Peprotech, (Rocky Hill, NJ). Reparixin (CSN15950) was purchased from CSNpharm; (Chicago, IL) and lenvatinib (E7080 A2174) was obtained from APExBIO (Houston, TX).

SMMC-7721 cell transfected with green fluorescent protein (GFP)-tagged Dicer-overexpressed lentivirus (pCMV-Dicer) or negative control lentivirus (pCMV-NC)¹⁷ was used for functional assay. The successful transfection of Dicer was confirmed by western blot analysis as described previously.¹⁷

Cell proliferation assay

Cell counting kit-8 (CCK-8; Dojindo, Kumamoto, Japan) was used for cell proliferation assay. Approximately 2 × 10³ cells were seeded into 96-well plates with 100 µL medium per well and incubated at 37°C with 5% CO₂. After incubation with 10 µL CCK-8 for 2 h, the absorbance of each cell was calculated with a microplate reader (Bio Tek, Winooski, VT) at wavelength of 450 nm at different time points (0, 24, 48, 72, and 96 h).

Wound healing assay

Cells were seeded on 6-well plates and cultured in DMEM medium with 10% FBS. When the cells reached approximately 100% density, 2 straight scratches were drawn using a 10 µL pipette tip in each well, on the surface of the plates. After washing twice with phosphate-buffered saline (PBS), the cells were cultured further in a fresh medium with 2% FBS for 24 h. An inverted microscope (Nikon, Tokyo, Japan) was used for capturing images at 0 and 24 h. Cell migration rates were calculated as the width of the difference between 24 h and 0 h divided by the initial width.

Invasion assay

Cell invasion capacity was assayed using 24-well transwell chambers with 8 µm pore size (Corning, New York, NY) precoated with Matrigel (1:20, BD Biosciences, NJ). First, the cells were cultured in DMEM with 2% FBS before the experiment for 12 to 24 h. We seeded 4 × 10⁴ or 6 × 10⁴resuspended cells with 200 µL serum-free DMEM in the upper chamber, while 600 µL DMEM medium with 10% FBS was placed in the lower chamber. After incubation for 48 h at 37°C in 5% CO₂ atmosphere, the cells in the upper chamber were wiped gently. Later, the remaining cells were fixed with 4% paraformaldehyde for 20 min and stained with 0.1% crystal violet for 30 min. The stained cells were counted using an inverted microscope (Nikon, Tokyo, Japan) in 5 random fields (magnification 200×) for each membrane.

Cytokines detection

Interleukin-8 level was detected by flow fluorescence immunomicrobeads assay. Cells were cultured for 72 h in an incubator, and the supernatant was used for IL-8 measurement using LEGENDplex Multi-analyte flow assay kit (Biolegend, San Diego, CA) according to manufacturer’s instructions as we have previously described.³⁰

Animal experiment

All animal experiments were approved by the Animal Ethics Committee of the Fourth Hospital of Hebei Medical University on December 3, 2021 (ID: 2021239). Twenty 4-week-old athymic male nude BALB/c mice were purchased from Charles River Laboratories [Beijing, China; permission no. SCXK (Jing) 2016–0006]. The 5 × 10⁶ SMMC-7721 pCMV-NC or pCMV-Dicer cells were resuspended in 200 µL serum-free DMEM and subcutaneously infected into the right shoulder of nude mice. After 12 days, the mice were randomly divided into 4 groups (n = 5): group pCMV-NC, group pCMV-Dicer, group pCMV-NC plus lenvatinib (lenvatinib 10 mg/kg), and group pCMV-Dicer plus lenvatinib (lenvatinib 10 mg/kg). As control, groups pCMV-NC and pCMV-Dicer were given 0.5% methyl cellulose instead. All groups were given intragastric administration once every 2 days. Tumor sizes were measured every 4 days and calculated using the equation V (mm³) = Length × (Width)²/2. The mice were all sacrificed by cervical dislocation 16 days after the lenvatinib treatment, and the tumor tissues were stored for future use.

Statistical analysis

All statistical analyses were performed using SPSS statistics software, version 21.0 (Chicago, IL, USA). The measurement data were presented as mean ± standard deviation. The differences between the 2 groups were obtained by Student’s t-test. P < .05 was considered to be statistically significant.

Results

Dicer suppresses HCC through IL-8

We overexpressed Dicer in HCC cell line of SMMC-7721 to evaluate the IL-8 level in the medium. As shown in Figure 1A, the secretion of IL-8 significantly decreased upon Dicer overexpression (P = .027), which indicated that Dicer inhibited IL-8 expression. The Dicer overexpression significantly inhibited the proliferation from 48 h to 96 h (Figure 1B, P < .01), migration (Figure 1C, P = .001) and invasion (Figure 1D, P = .000) of HCC cells when compared with those of pCMV-NC cells.

Figure 1.

IL-8 offsets the suppression of Dicer on HCC cells: (A) Dicer downregulates the secretion of IL-8 in SMMC-7721 cells. The level of IL-8 detected by flow fluorescence immunomicrobeads assay (n = 3). (B) The cell proliferation analysis by CCK-8 assay. (C) The cell migration analysis by wound healing assay. (D) The cell invasion analysis by transwell assay with 4 × 10⁴ cells in the upper chamber.

To evaluate whether Dicer inhibited HCC through IL-8 pathway, we incubated rhIL-8 with HCC cells at a concentration of 100 ng/mL for 96 h. RhIL-8 increased pCMV-NC cells proliferation from 48 to 96 h (Figure 1B, P = .000), migration (Figure 1C, P = .026) and invasion (Figure 1D, P = .000). It also neutralized Dicer-induced HCC cells inhibition on proliferation from 48 to 96 h (Figure 1B, P < .01), migration (Figure 1C, P = .003) and invasion (Figure 1D, P = .001) compared to pCMV-Dicer cells without rhIL-8. These data demonstrated that IL-8 could neutralize the Dicer-induced inhibition of HCC cells.

To further check whether the Dicer-modified HCC outcome through IL-8 pathway, the IL-8 receptor inhibitor of reparixin was used for subsequent analysis with 50 µg/mL work concentration. As shown in Figure 2, it inhibited cell proliferation from 72 to 96 h (Figure 2A, P < .05), migration (Figure 2B, P = .002) and invasion (Figure 2C, P = .000) after incubating pCMV-NC cells with reparixin. The same and more obvious trend was obtained for cell proliferation from 48 to 96 h (Figure 2A, P < .05), migration (Figure 2B, P = .008) and invasion (Figure 2C, P = .000) when incubated with pCMV-Dicer cells and reparixin. These data indicated that reparixin could enhance growth suppression induced by Dicer in HCC cells. Thus, Dicer inhibits HCC cells growth by regulating IL-8 pathway.

Figure 2.

Reparixin enhances the suppression of Dicer on HCC cells: (A) The cell proliferation analysis by CCK-8 assay. (B) The cell migration analysis by wound healing assay. (C) The cell invasion analysis by transwell assay with 4 × 10⁴ cells in the upper chamber.

Lenvatinib cooperated with dicer to inhibit HCC

We incubated SMMC-7721 cells with lenvatinib (E7080) at 20 µM concentration for 72 h. The secretion of IL-8 decreased significantly after lenvatinib treatment (Figure 3A, P = .000). This result showed that lenvatinib inhibited the expression of IL-8. In addition, lenvatinib inhibited pCMV-NC cells proliferation from 48 to 96 h (Figure 3B, P < .05), migration (Figure 3C, P = .000), and invasion (Figure 3D, P = .000). When co-cultured lenvatinib with pCMV-Dicer cells subsequently, it provided additive suppression with pCMV-Dicer cells on proliferation from 24 to 96 h (Figure 3B, P < .05), migration (Figure 3C, P = .000) and invasion (Figure 3D, P = .000). Next, we cocultured pCMV-NC or pCMV-Dicer cells with the same concentration of lenvatinib for 72 h. The results showed that the level of IL-8 in pCMV-Dicer cells was obviously decreased than that in pCMV-NC cells (Supplementary Figure S1, P = .006). These data demonstrated that Dicer combined with lenvatinib had a more obvious inhibitory effect on the expression of IL-8 compared with lenvatinib alone. So, we believed that lenvatinib enhanced Dicer-related suppression of HCC by decreasing IL-8 secretion in vitro.

Figure 3.

Lenvatinib has cooperative effect on the tumor inhibition of Dicer in vitro: (A) Lenvatinib downregulates the secretion of IL-8 in HCC cells (n = 3). (B) The cell proliferation analysis by CCK-8 assay. (C) The cell migration analysis by wound healing assay. (D) The cell invasion analysis by transwell assay with 6 × 10⁴ cells in the upper chamber.

The cooperation of Dicer and lenvatinib was evaluated in vivo. The growth of pCMV-Dicer xenograft decreased significantly compared to pCMV-NC xenograft from 12 to 16 days after implantation (Figure 4A and B, P < .05). In addition, lenvatinib provided additive suppression in both pCMV-NC group (Figure 4A and B, P < .01) from 8 to 16 days and pCMV-Dicer group (Figure 4A and B, P < .05) from 4 to 16 days. Furthermore, Dicer exhibited lenvatinib-related inhibition trend for HCC xenograft compared with pCMV-NC plus lenvatinib xenograft at a marginal statistical level in 16 days (Figure 4A and B, P = .074). These data suggested that lenvatinib could enhance the tumor inhibition of Dicer, and Dicer displayed its potential capability to enhance the antitumor effect of lenvatinib in vitro and vivo.

Figure 4.

Lenvatinib has cooperative effect on the tumor inhibition of Dicer in vivo (n = 5): (A) 5 × 10⁶ SMMC-7721 pCMV-NC or pCMV-Dicer transfected cells were infected into nude mice for 16 days. (B) Subcutaneous xenograft tumor volume was measured every 4 days.

Discussion

Based on Dicer-induced growth inhibition on HCC cells in vitro and in vivo,^17,31 we found that Dicer could inhibit HCC by downregulating IL-8. We also found that Dicer in cooperation with lenvatinib inhibited the growth of HCC via their common target of IL-8 pathway, which implied potential clinical application of Dicer expression on lenvatinib antitumor effect, but whether Dicer can overcome the lenvatinib resistance need to be furtherly evaluated. Elevated IL-8 in the tumor microenvironment plays a key role in the progression and metastasis of tumor.³² Interleukin-8 introduces granulocytic MDSCs to form neutrophil extracellular traps (NETs), which promote metastasis and thrombus formation.^33,34 Moreover, IL-8-CXCR1/2 axis may regulate cancer stem cells (CSCs) proliferation and self-renewal to promote tumor progression and metastasis.³⁵ The Dicer-IL-8 pathway might modify HCC development through the above mechanisms.

We have proven that Dicer inhibited HCC via downregulation of VEGF.¹⁷ Then, we suspected that Dicer might modify HCC outcome via IL-8-VEGF axis, but VEGF expression did not change upon IL-8 or reparixin incubation in HCC cells (data not shown). This has proved that a positive feedback loop exists between EMT and IL-8 and that IL-8 promotes the occurrence of EMT, whereas EMT induces the production of IL-8 in colon cancer correspondingly.^21,36,37 Dicer also modulates EMT via hypoxia-inducible factor 1α (HIF-1α) in HCC.³⁸ We compared the EMT markers upon IL-8 or raparixin incubation in pCMV-Dicer and pCMV-NC cells, and no expressional difference in these markers was found by western blot analysis (data not shown). Interleukin-8 expression was regulated by some miRNAs. The overexpression of miR-93 and miR-17 inhibited the production and release of IL-8; miR-140-3p inhibited only the expression of IL-8, while miR-155 promoted IL-8 production.^39-41 It is highly possible that the miRNA synthetase of Dicer might affect IL-8 secretion by regulating miRNA expression.

Interleukin-8 in peripheral blood and liver fibrotic tissue is associated with liver fibrosis.⁴² It activates hepatic stellate cells (HSCs) and stimulates alpha-smooth muscle actin (α-SMA) expression for the formation and activation of stress fibers.⁴³ The biomarkers for liver fibrosis did not change significantly when we cocultured IL-8 with HCC cells for 72 h (data not shown). However, these findings could not exclude the possibility that Dicer-mediated downregulation of IL-8 reduced HSCs fibrosis thereby inhibiting HCC progress.

Conclusions

In conclusion, Dicer in cooperation with lenvatinib inhibits HCC growth via downregulating IL-8. Dicer displayed its potential capability to enhance the antitumor effect of lenvatinib.

Supplemental Material

sj-docx-1-onc-10.1177_11795549231161212 – Supplemental material for Dicer Suppresses Hepatocellular Carcinoma via Interleukin-8 Pathway

Supplemental material, sj-docx-1-onc-10.1177_11795549231161212 for Dicer Suppresses Hepatocellular Carcinoma via Interleukin-8 Pathway by Xin Han, Jianhua Wu, Ziyue Sha, Ruixue Lai, Jianfei Shi, Lili Mi, Fei Yin and Zhanjun Guo in Clinical Medicine Insights: Oncology

Footnotes

Declaration of conflicting interests:

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding:

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Key Research and Development Projects of Hebei Province (grant no. 203777109D).

Author Contributions

ZG designed the original experiments. ZG and JW directed the progress of the experiments. XH performed the experiments. XH, ZS, RL, JS, LM, and FY interpreted the data and reviewed the manuscript. XH and ZG wrote the manuscript. All authors had final approval of the submitted and published versions.

ORCID iD

Xin Han

Supplemental Material

Supplemental material for this article is available online.

References

McGlynn

Petrick

El-Serag

. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73:4-13.

Lurje

Czigany

Bednarsch

, et al. Treatment strategies for hepatocellular carcinoma —a multidisciplinary approach. Int J Mol Sci. 2019;20:1465.

Llovet

Ricci

Mazzaferro

, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.

Finn

Qin

Ikeda

, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894-1905.

Kudo

Finn

Qin

, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163-1173.

Rimassa

Wörns

. Navigating the new landscape of secondline treatment in advanced hepatocellular carcinoma. Liver Int. 2020;40:1800-1811.

Torrens

Montironi

Puigvehí

, et al. Immunomodulatory effects of lenvatinib plus anti-programmed cell death protein 1 in mice and rationale for patient enrichment in hepatocellular carcinoma. Hepatology. 2021;74:2652-2669.

Personeni

Pressiani

Rimassa

. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date. J Hepatocell Carcinoma. 2019;6:31-39.

Bagga

Bracht

Hunter

, et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell. 2005;122:553-563.

10.

Bartel

. MicroRNAs: genomics, biogenesis, mechanism and function. Cell. 2004;116:281-297.

11.

Barbato

Ciotti

Serafino

Calissano

Cogoni

. Dicer expression and localization in post-mitotic neurons. Brain Res. 2007;1175:17-27.

12.

Dedes

Natrajan

Lambros

, et al. Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer. 2011;47:138-150.

13.

Zhang

Wang

, et al. Dysregulation of microRNA biosynthesis enzyme Dicer plays an important role in gastric cancer progression. Int J Clin Exp Pathol. 2014;7:1702-1707.

14.

Fan

Gao

, et al. Dicer is down-regulated in clear cell renal cell carcinoma and in vitro Dicer knockdown enhances malignant phenotype transformation. Urol Oncol. 2014;32:46.e9-417.

15.

Faggad

Kasajima

Weichert

, et al. Down-regulation of the microRNA processing enzyme Dicer is a prognostic factor in human colorectal cancer. Histopathology. 2012;61:552-561.

16.

Zhang

Wang

Liu

Zhao

Liu

Guo

. Prognostic significance of Dicer expression in hepatocellular carcinoma. Oncol Lett. 2016;11:3961-3966.

17.

Wang

Sha

, et al. Dicer enhances bevacizumab-related inhibition of hepatocellular carcinoma via blocking the vascular endothelial growth factor pathway. J Hepatocell Carcinoma. 2021;8:1643-1653.

18.

Schalper

Carleton

Zhou

, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med. 2020;26:688-692.

19.

Sanmamed

Perez-Gracia

Schalper

, et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann Oncol. 2017;28:1988-1995.

20.

Fernando

Castillo

Litzinger

, et al. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res. 2011;71:5296-5306.

21.

David

Dominguez

Hamilton

, et al. The IL-8/IL-8R axis: a double agent in tumor immune resistance. Vaccines (Basel). 2016;24:4.

22.

Highfill

Cui

Giles

, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med. 2014;6:237ra67.

23.

Chang

, et al. The interaction of interleukin-8 and PTEN inactivation promotes the malignant progression of head and neck squamous cell carcinoma via the STAT3 pathway. Cell Death Dis. 2020;11:405.

24.

Wen

Zhao

Huang

Wang

Miao

. IL-8 promotes cell migration through regulating EMT by activating the Wnt/β-catenin pathway in ovarian cancer. J Cell Mol Med. 2020;24:1588-1598.

25.

Inoue

Takeuchi

Matsuda

, et al. IL-8/CXCR2 signalling promotes cell proliferation in oesophageal squamous cell carcinoma and correlates with poor prognosis. Anticancer Res. 2021;41:783-794.

26.

Chen

Min

Wang

, et al. Loss of RACK1 promotes metastasis of gastric cancer by inducing a miR-302c/IL8 signaling loop. Cancer Res. 2015;75:3832-3841.

27.

Yang

Wang

Qin

, et al. Up-regulation of CXCL8 expression is associated with a poor prognosis and enhances tumor cell malignant behaviors in liver cancer. Biosci Rep. 2020;28:40.

28.

Sun

Wang

Sun

, et al. Interleukin-8 promotes integrin beta 3 upregulation and cell invasion through PI3K/Akt pathway in hepatocellular carcinoma. J Exp Clin Canc Res. 2019;38:449.

29.

Zhang

Gao

, et al. Hepatitis B-induced IL-8 promotes hepatocellular carcinoma venous metastasis and intrahepatic Treg accumulation. Cancer Res. 2021;81:2386-2398.

30.

Sha

Lai

Zhang

, et al. A polymorphism at the microRNA binding site in the 3’ untranslated region of is associated with breast cancer. DNA Cell Biol. 2020;39:1886-1894.

31.

Zhao

, et al. Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2. Sci Rep. 2021;11:6993.

32.

Catalano

Turdo

Di Franco

Dieli

Todaro

Stassi

. Tumor and its microenvironment: a synergistic interplay. Semin Cancer Biol. 2013;23:522-532.

33.

Alfaro

Teijeira

Onate

, et al. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin Cancer Res. 2016;22:3924-3936.

34.

Liu

Tian

, et al. The CXCL8-CXCR1/2 pathways in cancer. Cytokine Growth Factor Rev. 2016;31:61-71.

35.

Brandolini

Cristiano

Fidoamore

, et al. Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling. Oncotarget. 2015;6:43375-43394.

36.

Bates

DeLeo

Mercurio

. The epithelial-mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res. 2004;299:315-324.

37.

Cheng

Tan

, et al. CCL20 and CXCL8 synergize to promote progression and poor survival outcome in patients with colorectal cancer by collaborative induction of the epithelial-mesenchymal transition. Cancer Lett. 2014;348:77-87.

38.

Ibrahim

Schmithals

Kowarz

, et al. Hypoxia causes downregulation of dicer in hepatocellular carcinoma, which is required for upregulation of hypoxia-inducible factor 1α and epithelial-mesenchymal transition. Clin Cancer Res Jul. 2017;23:3896-3905.

39.

Debnath

Neamati

. Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases. Theranostics. 2017;7:1543-1588.

40.

Jundi

Greene

. Transcription of interleukin-8: how altered regulation can affect cystic fibrosis lung disease. Biomolecules. 2015;5:1386-1398.

41.

Dileepan

Sarver

Rao

Panettieri

Jr Subramanian

Kannan

. MicroRNA mediated chemokine responses in human airway smooth muscle cells. PLoS ONE. 2016;11:e0150842.

42.

Langhans

Krämer

Louis

, et al. Intrahepatic IL-8 producing Foxp3⁺CD4⁺ regulatory T cells and fibrogenesis in chronic hepatitis C. J Hepatol. 2013;59:229-235.

43.

Dong

Zheng

. Interleukin-8: a critical chemokine in biliary atresia. J Gastroenterol Hepatol. 2015;30:970-976.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.17 MB